GNGabriele Negro

Gabriele Negro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gabriele Negro has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Left bundle branch area pacing vs. right ventricular pacing in post-transcatheter aortic valve implantation patients: a retrospective propensity-matched analysis

    by Zarko Calovic, Raffaele Salerno, Marco Gamardella, Alessandro Fuga, Alessia Vuturo, Antonio Boccellino, Davide Morciano, Antonio Izzo, Michele Morosato, Gabriele Negro, et al.

    Transcatheter aortic valve implantation (TAVI) is an established treatment for severe aortic stenosis across a wide range of patients.1 Despite technological advances, conduction disturbances remain frequent, and many patients require permanent pacemaker (PPM) implantation.2,3 Conventional right ventricular pacing (RVP) may induce electrical and mechanical dyssynchrony, promoting left ventricular dysfunction and heart failure.4 Left bundle branch area pacing (LBBAP) offers a more physiological activation by engaging the native conduction system.5 Although beneficial in non-TAVI populations,6,7 its role after TAVI is not well defined. This study compares outcomes of LBBAP vs. RVP in post-TAVI patients requiring PPM implantation.


  • Top Cited Papers
    Open Access

    Semaglutide as adjunctive therapy to catheter ablation in obesity-related paroxysmal atrial fibrillation

    by Giuseppe Ciconte, Raffaele Salerno, Alessandro Fuga, Alessia Vuturo, Antonio Boccellino, Gabriele Negro, Roberto Rondine, Marco Ballarotto, Cristiano Ciaccio, Antonio Izzo, et al.

    Aims: Obesity adversely affects atrial fibrillation (AF) outcomes and is associated with higher recurrence after catheter ablation. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) promote weight loss and improve metabolic inflammation, but their role as adjuncts to ablation has not been completely defined. This study investigated the impact of semaglutide on post-ablation rhythm outcomes in obese patients with AF. Methods and results: This single-centre, propensity-matched study included obese patients [body mass index (BMI) ≥ 30 kg/m²] undergoing first-time catheter ablation for paroxysmal AF (2019–2024). Patients who initiated semaglutide within 3 months before or 1 month after ablation were compared with matched controls who did not receive GLP-1RA therapy. All patients underwent continuous rhythm monitoring using implantable cardiac monitors. The primary endpoint was any atrial tachyarrhythmia recurrence beyond a 2-month blanking period. The final cohort included 181 semaglutide-treated patients and 181 controls with matched clinical and procedural characteristics. At 18-month follow-up, freedom from recurrence was 80.2% vs. 65.2%; semaglutide was associated with a significantly lower risk of recurrence (hazard ratio 0.52; 95% confidence interval 0.34–0.78; P = 0.002). Weight and BMI decreased significantly in the semaglutide group (−11.8 ± 3.8 kg; −4.0 ± 1.4 kg/m²) compared with controls (−1.9 ± 1.2 kg; −0.3 ± 0.8 kg/m²; both P < 0.001). A substantial proportion of treated patients achieved ≥10% weight reduction. Conclusion: Glucagon-like peptide-1 receptor agonist therapy using semaglutide is associated with a reduced risk of AF recurrence in obese patients undergoing AF catheter ablation, indicating its potential as an adjunctive treatment. Further studies are needed to confirm these findings and elucidate the effects of GLP-1RA on AF recurrence.


  • Open Access

    Epicardial ablation in high-risk Brugada syndrome to prevent ventricular fibrillation: results from a randomized clinical trial

    by Carlo Pappone, Giuseppe Ciconte, Gabriele Vicedomini, Emanuele Micaglio, Antonio Boccellino, Gabriele Negro, Luigi Giannelli, Roberto Rondine, Pasquale Creo, Adriana Tarantino, et al.

    Aims: Epicardial ablation for Brugada syndrome (BrS) has shown promise in reducing ventricular fibrillation (VF), but its role remains controversial due to the lack of randomized trials. This study evaluates the efficacy of catheter ablation in high-risk BrS patients. Methods and results: This prospective, single-centre, randomized (2:1) study enrolled BrS patients with cardiac arrest (CA) or appropriate ICD therapies. All patients had an ICD and were randomized to undergo epicardial ablation (ablation group) or no ablation (control group). Enrolment began in September 2017 and prematurely terminated in February 2024. The primary endpoint was freedom from VF recurrences. Secondary endpoints included procedure safety, ICD-related complications, and quality-of-life assessment. Forty patients (83% male, mean age 43.7 ± 12.1) were randomized: 26 in the ablation group and 14 in the control group. Thirty-six patients received appropriate ICD therapies before enrolment: 24 (92%) in the ablation group and 12 (86%) in the control group. One patient in the ablation group experienced a post-procedural pericardial effusion requiring pericardiocentesis. Thirteen patients (33%) had major ICD-related complications. After a mean follow-up of 4.0 ± 1.7 years, freedom from VF recurrence was 96% (25/26) in the ablation group and 50% (7/14) in the control group (P < 0.001). No unexplained or arrhythmic deaths occurred during follow-up. Conclusion: Epicardial catheter ablation was associated with a reduction in VF recurrence compared with ICD therapy alone. These findings support the use of epicardial ablation in high-risk BrS patients. ClinicalTrials.gov: ID NCT03294278


  • Open Access

    Anatomical-guided third-generation laser balloon ablation for the treatment of paroxysmal atrial fibrillation assessed by continuous rhythm monitoring: results from a multicentre prospective study

    by Giuseppe Ciconte, Marco Schiavone, Giovanni Rovaris, Raffaele Salerno, Marzia Giaccardi, Elisabetta Montemerlo, Alessio Gasperetti, Elena Piazzi, Gabriele Negro, Stella Cartei, et al.

    The third-generation laser balloon (LB3) is an established ablation device for pulmonary vein isolation (PVI) that allows direct visualization of the anatomical target. Equipped with an automatic circumferential laser delivery modality, it aims at continuous circumferential PVI, improving both acute and clinical outcomes. We sought to evaluate the clinical efficacy of LB3 ablation using an anatomical-based approach without verifying electrical isolation. Among 257 paroxysmal AF patients undergoing LB3 ablation across four Italian centres, 204 (72% male, mean age 60.4 ± 11.1 years) were included. The primary endpoint was freedom from any atrial tachyarrhythmia (ATa) recurrence after the blanking period (BP), assessed with implantable cardiac monitors (ICMs). All pulmonary veins (PVs) were targeted using the LB3, with the RAPID mode used on an average of 96 ± 8, 86 ± 19, 98 ± 11, and 84 ± 15% for the left superior, left inferior, right superior, right inferior PV, and left common ostium, respectively. Freedom from arrhythmia recurrences was 84.8% at 1, 80.4% at 2, and 76.0% at 3 years. An ATa burden ≥ 5% was documented in 2.5, 4.4, and 5.4% at 1, 2, and 3 years, respectively. Relapses during the BP [hazard ratio (HR) = 2.182, P = 0.032] and left atrial dilation (HR = 1.964, P = 0.048) were independent predictors of recurrences. Anatomical-guided LB3 ablation for paroxysmal AF is a safe and effective approach, providing excellent clinical outcomes as assessed by ICM over nearly 3 years of follow-up.


  • Open Access

    Cardiac Cross-Reactivity of NaV Autoantibodies in Metastatic Breast Cancer: A Possible Trigger for Sudden Cardiac Death

    by Carlo Pappone, Adriana Tarantino, Dario Melgari, Marco Piccoli, Giuseppe Ciconte, Anthony Frosio, Emanuele Micaglio, Serena Calamaio, Chiara Vantellino, Federica Cirillo, et al.

    Background and Aims Patients with metastatic breast cancer have an increased risk of sudden cardiac death (SCD) that cannot be fully explained by cardiotoxic treatments. Recent evidence shows that autoantibodies targeting the cardiac NaV1.5 sodium channel in Brugada syndrome (BrS) can trigger arrhythmias and elevate SCD risk. Similarly, autoantibodies against the neonatal NaV1.5 isoform have been found in metastatic breast cancer patients. Given the high homology between these NaV1.5 isoforms, we investigated whether these autoantibodies cross-react with the cardiac isoform, potentially contributing to SCD in this population. Methods Plasma from twenty metastatic breast cancer patients was analyzed for anti-NaV1.5 autoantibodies using HEK293A cells expressing the NaV1.5 protein, followed by Western blotting. The effects of these autoantibodies on sodium current density were assessed in cellular models and wild-type mice, with electrocardiographic monitoring after plasma infusion. Results Fifteen plasma samples from metastatic breast cancer patients tested positive for anti-NaV1.5 autoantibodies, significantly reducing sodium current density in vitro. Mice injected with these plasma samples developed severe arrhythmias and a Brugada syndrome-like ECG pattern. In contrast, plasma samples either without the autoantibodies or with IgG depletion showed no such effects, underscoring the role of IgG in sodium current reduction and confirming the pathogenicity of the autoantibodies. Conclusions This study demonstrates that anti-NaV1.5 autoantibodies in metastatic breast cancer patients can cross-react with the cardiac NaV1.5 isoform, potentially leading to fatal arrhythmias. These findings highlight a novel mechanism for the high SCD rate in this population and suggest that therapies involving sodium blockers should be used with caution to avoid exacerbating this risk. Reliable diagnostic tests and targeted therapies are urgently needed to mitigate SCD risk in affected patients.

  • Open Access

    NaV1.5 autoantibodies in Brugada syndrome: pathogenetic implications

    by Adriana Tarantino, Giuseppe Ciconte, Dario Melgari, Anthony Frosio, Andrea Ghiroldi, Marco Piccoli, Marco Villa, Pasquale Creo, Serena Calamaio, Valerio Castoldi, et al.

    Patients suffering from Brugada syndrome (BrS) are predisposed to life-threatening cardiac arrhythmias. Diagnosis is challenging due to the elusive electrocardiographic (ECG) signature that often requires unconventional ECG lead placement and drug challenges to be detected. Although NaV1.5 sodium channel dysfunction is a recognized pathophysiological mechanism in BrS, only 25% of patients have detectable SCN5A variants. Given the emerging role of autoimmunity in cardiac ion channel function, this study explores the presence and potential impact of anti-NaV1.5 autoantibodies in BrS patients. Using engineered HEK293A cells expressing recombinant NaV1.5 protein, plasma from 50 BrS patients and 50 controls was screened for anti-NaV1.5 autoantibodies via western blot, with specificity confirmed by immunoprecipitation and immunofluorescence. The impact of these autoantibodies on sodium current density and their pathophysiological effects were assessed in cellular models and through plasma injection in wild-type mice. Anti-NaV1.5 autoantibodies were detected in 90% of BrS patients vs. 6% of controls, yielding a diagnostic area under the curve of .92, with 94% specificity and 90% sensitivity. These findings were consistent across varying patient demographics and independent of SCN5A mutation status. Electrophysiological studies demonstrated a significant reduction specifically in sodium current density. Notably, mice injected with BrS plasma showed Brugada-like ECG abnormalities, supporting the pathogenic role of these autoantibodies. The study demonstrates the presence of anti-NaV1.5 autoantibodies in the majority of BrS patients, suggesting an immunopathogenic component of the syndrome beyond genetic predispositions. These autoantibodies, which could serve as additional diagnostic markers, also prompt reconsideration of the underlying mechanisms of BrS, as evidenced by their role in inducing the ECG signature of the syndrome in wild-type mice. These findings encourage a more comprehensive diagnostic approach and point to new avenues for therapeutic research. Role of anti-NaV1.5 autoantibodies in Brugada syndrome. It demonstrates how these autoantibodies, when present in patient plasma, can elicit the coved-type ST-segment elevation resembling the human type 1 Brugada syndrome electrocardiographic pattern in wild-type mice and significantly reduce sodium current density, supporting their diagnostic and pathogenic significance in the disease. BrS, Brugada syndrome; ECG, electrocardiographic; IgG, immunoglobulin G.


  • Open Access

    High-risk Brugada syndrome: factors associated with arrhythmia recurrence and benefits of epicardial ablation in addition to implantable cardioverter defibrillator implantation

    by Vincenzo Santinelli, Giuseppe Ciconte, Francesco Manguso, Luigi Anastasia, Emanuele Micaglio, Zarko Calovic, Gabriele Vicedomini, Beniamino Mazza, Mattia Vecchi, Valerio Mecarocci, et al.

    This study aims to evaluate the prognostic impact of the arrhythmogenic substrate size in symptomatic Brugada syndrome (BrS) as well as to validate the long-term safety and effectiveness of epicardial radiofrequency ablation (RFA) compared with no-RFA group. In this prospective investigational long-term registry study, 257 selected symptomatic BrS patients with implantable cardioverter defibrillator (ICD) implantation were included. Among them, 206 patients underwent epicardial RFA and were monitored for over 5 years post-ablation (RFA group), while 51 patients received only ICD implantation declining RFA. Primary endpoints included risk factors for ventricular fibrillation (VF) events pre-ablation and freedom from VF events post-ablation. In the RFA group, BrS substrates were identified in the epicardial surface of the right ventricle. During the pre-RFA follow-up period (median 27 months), VF episodes and VF storms were experienced by 53 patients. Independent risk factors included substrate size [hazard ratio (HR), 1.13; 95% confidence interval (CI), 1.08–1.18; P < 0.001], aborted cardiac arrest (HR, 2.98; 95% CI, 1.68–5.28; P < 0.001), and SCN5A variants (HR, 2.22; 95% CI, 1.15–4.27; P = 0.017). In the post-RFA follow-up (median 40 months), the RFA group demonstrated superior outcomes compared with no-RFA (P < 0.001) without major procedure-related complications. Our study underscores the role of BrS substrate extent as a crucial prognostic factor for recurrent VF and validates the safety and efficacy of RFA when compared with a no-RFA group. Our findings highlight the importance of ajmaline in guiding epicardial mapping/ablation in symptomatic BrS patients, laying the groundwork for further exploration of non-invasive methods to guide informed clinical decision-making. Upper panel: Independent predictors determined by multivariable Cox analysis along with the respective Kaplan–Meier curves. Middle panel: Epicardial maps of the Brugada syndrome substrate before and after ajmaline infusion pre-ablation, as well as after ajmaline infusion post-ablation. Notably, after the ablation, the substrate is eliminated, even in the presence of ajmaline infusion. Lower panel: Long-term benefits of epicardial ablation in comparison with the no-radiofrequency ablation group.


  • Open Access

    Arrhythmogenic substrate elimination for safe testosterone therapy in symptomatic Brugada syndrome patients

    by Gabriele Negro, Antonio Boccellino, Antonio Napolano, Emanuele Micaglio, Zarko Calovic, Luigi Anastasia, Giuseppe Ciconte

    Background: Brugada Syndrome (BrS) is a cardiogenetic disease known for its association with sudden cardiac death (SCD) in individuals with structurally normal hearts. The prevalence of BrS is higher in males, who also face a greater risk of SCD. Its higher prevalence and worse outcome in male subjects may be due to testosterone effects on ion channels expression and function. The influence of testosterone on cardiac action potentials, both genomically and non-genomically, underscores its potential role in unmasking the syndrome and triggering life-threatening arrhythmias. Notably, testosterone replacement therapy (TRT), used for hypogonadism and gender reassignment, has been linked to BrS unmasking. The role of epicardial ablation in symptomatic BrS patients where hormonal therapy cannot be discontinued is unknown. Methods and results: In this study we describe the first two cases of substrate mapping and ablation in BrS patients experiencing arrhythmic events while on TRT. In both cases, high-density epicardial mapping revealed abnormal areas of prolonged and fragmented electrograms in the right ventricular (RV) outflow tract and anterior wall. These abnormalities were completely abolished by radiofrequency ablation (RFA). After ablation, both patients showed a persistent normalization of the ECG and were free from ventricular arrhythmias at follow-up, despite ongoing TRT. Conclusion: RFA can be considered as a therapeutic option in symptomatic BrS patients with a high-risk profile who cannot discontinue TRT, being essential for restoring their normal physiology or preserving their sexual identity. As testosterone use is increasing, further studies are warranted to define a standardized diagnostic and therapeutic strategy in this specific subset of BrS patients.


  • Open Access

    Sudden death of a patient with epilepsy: When Brugada syndrome mimicry can be fatal

    by Gabriele Negro, Giuseppe Ciconte, Valeria Borrelli, Roberto Rondine, Vincenzo Maiolo, Carlo Pappone